Establishment of a method for predicting therapeutic efficacy and adverse effects of drug therapy for hepatocellular carcinoma using tests related to the intestinal microbiota and elucidation of the mechanism
Not Applicable
- Conditions
- Chronic Hepatitis, Hepatocellular Carcinoma, Liver cirrhosis
- Registration Number
- JPRN-UMIN000052641
- Lead Sponsor
- agoya University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with galactosemia Patients who have experienced allergies to foods containing sugar alcohols Patients with poorly controlled diabetes Patients who wish to be excluded from the study Patients who are pregnant, nursing, possibly pregnant or wish to become pregnant, or wishing to raise children Other patients whom the physician has judged to be inappropriate for safely conducting this trial
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method In patients with hepatocellular carcinoma undergoing chemotherapy, identifying differences in gut microbiota and intestinal permeability between the groups with favorable treatment outcomes (where the response during administration is evaluated as stable disease (SD) or better, according to m-RECIST and RECIST criteria) and the groups with unfavorable outcomes (where the response during administration is evaluated as progressive disease (PD)).
- Secondary Outcome Measures
Name Time Method Identification of gut microbiota and differences in intestinal permeability associated with adverse events during the treatment period.